105 0 Kommentare
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results - Seite 2
Appointed Andrew Moin, Partner and Analyst at Sessa Capital, a New York based investment advisor registered with the SEC, to the SAB Board of Directors. Mr. Moin has
been with Sessa since 2012, where he works on idea generation, research, and investment implementation. He has also been deeply involved in the type 1 diabetes community for over 20 years, including
as a volunteer and member of the Young Leadership Committee of the New York City Chapter of the JDRF and an early supporter of multiple fundamental diabetes research and innovation projects.
Appointed Katie Ellias, Managing Partner at JDRF T1D Fund, to the SAB Board of Directors. The JDRF T1D Fund LLC is a venture philanthropy fund with approximately $200
million in assets, including an investment in SAB. Ms. Ellias joined the T1D Fund in 2018 where she has led several investments in companies developing T1D-oriented therapies. She has also served as
a director on the board of several companies, including, DiogenX, Veralox Therapeutics, i2O Therapeutics, and Capillary Biomedical.
Welcomed Erick Lucera to our Board of Directors. Mr. Lucera, a 30-year veteran of the biotechnology and medical device industry, has held executive positions at
several healthcare companies, most recently as Chief Financial Officer of Editas Medicine.
Hosted 2023 R&D Day virtual and in-person events, affirming SAB’s strategic focus in the autoimmunity space with SAB-142, a disease-modifying fully human hIgG
aimed at preventing onset or disease progression of Type 1 Diabetes, and subsequently can be expanded into other immunology indications.
Upcoming Corporate Presentation
Samuel J. Reich, Chairman and CEO of SAB Biotherapeutics, will present on behalf of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024, at
1:30 pm ET. The company will also participate in virtual 1:1 meetings. A replay of Mr. Reich’s presentation will be archived on the SAB Biotherapeutics website for up to one year.
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results - Seite 2
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) - SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million …